• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
ZHU Ling, QIN Chao, WU Jinlian, CHEN Yuhong, YIN Lifang. Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2019, 50(1): 53-58. DOI: 10.11665/j.issn.1000-5048.20190107
Citation: ZHU Ling, QIN Chao, WU Jinlian, CHEN Yuhong, YIN Lifang. Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets[J]. Journal of China Pharmaceutical University, 2019, 50(1): 53-58. DOI: 10.11665/j.issn.1000-5048.20190107

Preparation and in vitro evaluation of pregabalin controlled porosity osmotic pump tablets

More Information
  • In this study, pregabalin controlled porosity osmotic pump tablets which are taken once a day were prepared. Single-factor tests were carried out to investigate the influence of excipients and manufacturing process. The formulation was optimized through orthogonal experiment on three levels of three significant factors including the amount of sodium citrate, and polyethylene glycol 400 and coating weight gain. On the basis of the results of the single-factor tests and the orthogonal experiment, optimal formulation and manufacturing process were obtained. The final tablet formulation contained pregabalin(82. 5 mg), microcrystalline cellulose(40%), sodium citrate(27. 5%), magnesium stearate(0. 5%)and 5% povidone K30 solution as the tablet binder; the coating formulation consisted of cellulose acetrate and 60% of polyethylene glycol 400 as a porogen; the coating weight gain was 3%. In vitro drug release kinetic study suggested that the drug release from controlled porosity osmotic pump tablets was mainly driven by osmotic pressure, which was barely affected by the pH of the release medium. The drug release behavior of the tablets within 12 hours complied with zero-order release rule and the linear correlation coefficient was 0. 991 6. The obtained porosity osmotic pump tablets could effectively slow the drug release rate, reduce concentration fluctuation and improve the safety and convenience for the patients, hence with broad prospects.
  • [1]
    Li Z,Taylor CP,Weber M,et al.Pregabalin is a potent and selective ligand for α(2)δ-1 and α(2)δ-2 calcium channel subunits.[J].Eur J Pharmacol,2011,667(1/2/3):80-90.
    [2]
    Stahl SM, Porreca F, Taylor CP, et al. The diverse therapeutic actions of pregabalin:is a single mechanism responsible for several pharmacological activities[J]?Trends Pharmacol Sci,2013,34(6):332-339.
    [3]
    Tassone DM,Boyce E,Guyer J,et al.Pregabalin:a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain,partial-onset seizures,and anxiety disorders[J].Clin Ther,2007,29(1):26-48.
    [4]
    Bockbrader HN,Radulovic LL,Posvar EL,et al.Clinical pharmacokinetics of pregabalin in healthy volunteers[J].J Clin Pharmacol,2010,50(8):941-950.
    [5]
    Shokri J,Ahmadi P,Rashidi P,et al.Swellable elementary osmotic pump(SEOP):an effective device for delivery of poorly water-soluble drugs[J].Eur J Pharm Biopharm,2008,68(2):289-297.
    [6]
    Chen FW,Guo Z,Li HY,et al.Correlation of Fuzilizhong chemome release from osmotic pump tablets and intrinsic dissolution characteristics from powders[J].J China Pharm Univ(中国药科大学学报),2012,43(4):329-333.
    [7]
    Li XD,Pan WS,Nie SF,et al.Studies on controlled release effervescent osmotic pump tablets from traditional chinese medicine compound recipe[J].J Control Release,2004,96(3):359-367.
    [8]
    Adibkia K,Hanaee J,Ghanbarzadeh S,et al.Micro-suspension coating method:a new approach in formulation and development of controlled porosity osmotic pump systems[J].Drug Res,2013,64(4):203-207.
    [9]
    Kanagale P,Lohray BB,Misra A,et al.Formulation and optimization of porous osmotic pump-based controlled release system of oxybutynin.[J].AAPS Pharmscitech,2007,8(3):E13-E19.
    [10]
    Li GJ,Wang YJ,Chen HM,et al.Can semipermeable membranes coating materials influence in-vivo performance for paliperidone tri-layer ascending release osmotic pump tablet: in vitro evaluation and in vivo pharmacokinetics study[J].Asian J Pharm Sci,2015,10(2):128-137.
    [11]
    He W,Xue WD,Tang B.Optimization Test Design Method and Data Analysis[M]. Chemical Industry Press(化学工业出版社),2012.
    [12]
    Mohanty S,Sahu M,Sirisha A.Osmotic pump a novel approach to control drug delivery[J].Indo Am J Pharm Res,2014,4(5):2367-2373.
    [13]
    Xu XH,Liao LY,Jiang T. Release mechanism of PNS microporous membrane osmotic pump tablets[J].Chin J Exp Tradit Med Form(中国实验方剂学杂志),2012,18(8):12-14.
  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.
  • Cited by

    Periodical cited type(9)

    1. 蔡鸿飞,张琴,关伟键,杨阳,袁诚,许文东. 不同干燥方式对灵芝孢子粉中灵芝孢子油过氧化值的影响. 广东化工. 2024(01): 28-30 .
    2. 林志彬. 灵芝孢子油的药效物质基础研究进展. 菌物研究. 2024(01): 79-87 .
    3. Jianying Liu,Binzhi Zhang,Leqi Wang,Shasha Li,Qinqiang Long,Xue Xiao. Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: A review. Chinese Herbal Medicines. 2024(03): 375-391 .
    4. 武美华,张胜男,敬隆鑫,律凤霞. 灵芝的活性成分及其药理作用的研究进展. 中国林副特产. 2023(02): 76-79 .
    5. 夏凤娜,关小莺,陈少丹,陈秋颜,张一帆,杨小兵. 灵芝孢子粉脂质成分HPLC-ELSD指纹图谱构建及含量测定. 食用菌学报. 2023(06): 52-59 .
    6. 井子良,吴纯宇,张慧敏,孙建博. 灵芝孢子油番茄红素复合物的抗肿瘤作用. 现代食品科技. 2022(09): 46-51 .
    7. 李志强,何玉霞. 灵芝多糖对人肺癌A549细胞增殖凋亡的作用. 现代食品科技. 2021(05): 38-42 .
    8. 张琴,李康强,杨阳,张圳,蔡鸿飞,许文东. 不同提取方式的灵芝孢子油品质研究. 广东化工. 2021(11): 48-49 .
    9. 包县峰,徐勇,刘维明,王星丽,孙培龙,张安强. 灵芝孢子粉生物活性成分及药理作用. 食品工业科技. 2020(06): 325-331 .

    Other cited types(6)

Catalog

    Article views (897) PDF downloads (1154) Cited by(15)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return